“apple-tree-partners” Archives

in
Entry Author Date Location
Syntimmune Snares $50M to Test Autoimmune Drug in Two Rare Diseases 06/21/17 New York
Boston Tech Watch: Uber, Causeway Media, Cure Forward, Tive & More 06/09/17 Boston
Visterra, Braeburn Stumble After Solid ’17 Start for Bio IPOs 02/10/17 Boston
Syntimmune Lands $8,000,000 Series A Round 11/21/16 New York
Rox Medical Obtains $40,000,000 Series E Funding Round 09/07/16 San Diego
VytronUS Receives $49,000,000 Series C Financing 08/01/16 San Francisco
East Coast Biotech Roundup: Harvard’s Haul, Patent Fights, Padlock & More 03/24/16 Boston
Syntimmune Lands $1,000,000 New Financing 03/23/16 New York
NY Bio Startup Syntimmune Gets $10M From Baxalta, Apple Tree 03/22/16 New York
Corvidia Therapeutics Secures $26,000,000 Series A Funding 02/18/16 Boston
Pharmas, Others Bet $33M More on Aileron’s P53 Peptide Drug 10/29/14 Boston
Tokai Bags $97M For Prostate Cancer Drug in Upsized IPO 09/17/14 Boston
Tokai, Chasing the Field in Prostate Cancer, Files For IPO 08/12/14 Boston
East Coast Biotech Roundup: Moderna, Aileron, Seres, & More 11/22/13 Boston
Big Pharma Quartet Puts $30M Behind Aileron’s P53 Peptide Drug 11/18/13 Boston
Aileron Therapeutics Garners $30,000,000 Series E Funding Round 11/18/13 Boston
East Coast Life Sciences Roundup: Termeer, Atlas, OSI Pharma & More 05/17/13 Boston
Tokai Pharmaceuticals Obtains $35,500,000 Series E Round 05/15/13 Boston
Tokai Looks to Follow Fast Behind J&J, Medivation in Prostate Cancer 02/13/13 Boston
Aileron Therapeutics Garners $12,000,000 Series D Financing 01/14/13 Boston
Tokai Gets $23M, Eleven Therapeutics Hires New CEO, Ariad Drug Advances, & More Boston-Area Life Sciences News 09/23/11 Boston
Mascoma Seeks IPO, Tokai Takes in $23M, Boston-Power Gets $125 for Shift to China, & More Boston-Area Deals News 09/21/11 Boston
Tokai Snaps Up $23M From Novartis and Apple Tree to Challenge Leaders in Prostate Cancer 09/20/11 Boston
Tokai Pharmaceuticals Obtains $23,000,000 Series D Financing Round 09/20/11 Boston
Aileron Inks Deal with Roche, Worth Up to $1.1B, to Develop Stapled Peptide Drugs 08/24/10 Boston
Celgene Agrees to Acquire Gloucester Pharma for $340M Cash Upfront, $300M Later 12/07/09 Boston
Tokai Pushes Edge With Three-Pronged Attack on Prostate Cancer 11/10/09 Boston
Gloucester Pharma Wins FDA Approval of Drug for Rare Skin Cancer 11/05/09 Boston
Top 10 (+ 1) New England Venture Deals of Q3 2009 10/20/09 Boston
Gloucester Wins Recommendation from FDA Panel for Lymphoma Drug 09/02/09 Boston
Page 1 of 2 next page »